Studies

Alexion plans to acquire Achillion

Alexion Pharmaceuticals, the maker of eculizumab (Soliris®) and ravulizumab (Ultomiris®), has reached an agreement with Achillion Pharmaceuticals to provide the smaller biopharmaceutical company for approximately $ 930 million (equivalent to approximately € 840 million) take over. If Achillion shareholders and regulators agreeREAD MORE

11th Essen patient seminar successful

On September 28, 2019, the Essen University Hospital held its 11th patient and family seminar on PNH and AA. Under the direction of Prof Dr Ulrich Dührsen and PD Dr Alexander Röth as usual a varied and exciting program was offered that left enough space for breaks and exchanges between the more than 200 participants. READ MORE

positive opinion for ravulizumab

Ravulizumab (Ultomiris®), the successor to eculizumab (Soliris®) by the manufacturer Alexion Pharmaceuticals, Inc., has been approved by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines AgencyREAD MORE
Loading new posts...
No more posts